Spyre Therapeutics (SYRE) Preferred Stock Liabilities (2015 - 2024)

Spyre Therapeutics (SYRE) posted Preferred Stock Liabilities of $253.4 million for Q1 2024, up 199.69% on a QoQ basis from $84.6 million in Q4 2023.

Spyre Therapeutics (SYRE) Preferred Stock Liabilities (2015 - 2024) Analysis & Trends

Spyre Therapeutics' Preferred Stock Liabilities history runs 4 years deep, the most recent figure standing at $253.4 million for Q1 2024.

Quarterly Preferred Stock Liabilities changed N/A year-over-year to $253.4 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $253.4 million (changed N/A YoY) and the FY2023 annual result came in at $84.6 million, changed N/A from the prior year.
Preferred Stock Liabilities was $253.4 million for Q1 2024 at Spyre Therapeutics, up from $84.6 million in the prior quarter.
Across five years, Preferred Stock Liabilities topped out at $387.1 million in Q3 2023 and bottomed at $84.6 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Spyre Therapeutics	257.83 Mn	257.83 Mn	-	-

Download Data